POINT Biopharma Global Inc logo

PNT

POINT Biopharma Global Inc

$8.83

Earnings Summary

Revenue
$0Mn
Net Profits
$-16.38Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

POINT Biopharma Global Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, POINT Biopharma Global Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

POINT Biopharma Global Inc’s net profit fell -1070.84% since last year same period to $-16.38Mn in the Q1 2022. On a quarterly growth basis, POINT Biopharma Global Inc has generated -15.38% fall in its net profits since last 3-months.

Net Profit Margins:

POINT Biopharma Global Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, POINT Biopharma Global Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the POINT Biopharma Global Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.22
EPS Estimate Current Year
-0.22

Highlights

EPS Estimate Current Quarter:

POINT Biopharma Global Inc’s earning per share (EPS) estimates for the current quarter stand at -0.22 - a -4.76% fall from last quarter’s estimates.

EPS Estimate Current Year:

POINT Biopharma Global Inc’s earning per share (EPS) estimates for the current year stand at -0.22.

Key Ratios

Key ratios of the POINT Biopharma Global Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.18
Return on Assets (ROA)
-0.17
Return on Equity (ROE)
-0.29
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

POINT Biopharma Global Inc’s earning per share (EPS) fell -124.44% since last year same period to -0.18 in the Q1 2022. This indicates that the POINT Biopharma Global Inc has generated -124.44% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. POINT Biopharma Global Inc’s return on assets (ROA) stands at -0.17.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. POINT Biopharma Global Inc’s return on equity (ROE) stands at -0.29.

Dividend Per Share (DPS):

POINT Biopharma Global Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-13
-0.21
-0.18
14.29%

Company Information

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), and industry-leading manufacturing capabilities and supply chain to revolutionize theragnostic drug development and radioligand commercialization.

Organisation
POINT Biopharma Global Inc
Headquarters
4850 West 78th Street, Indianapolis, IN, United States, 46268